文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

NRG GY017 宫颈癌放疗质量与工作流程:Atezolizumab 联合放化疗

Radiation Quality and Workflow in NRG GY017: Anti-PD-L1 (Atezolizumab) as an Immune Primer or Concurrently With Radiation Therapy for Node-Positive Locally Advanced Cervical Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-05-25

NRG GY-017 是一项随机试验,评估抗PD-L1抗体Atezolizumab在局部晚期宫颈癌中作为免疫启动或与放化疗同步使用的效果。经过审查和修改后,所有患者均在治疗前达到方案标准。

要点

  • 重大偏差中11例源于轮廓问题(5例肠道、6例淋巴结),2例源于体积或剂量分布错误。
  • 中心审查使所有患者治疗前达到方案标准。

核心结论

  • 35%的基线提交的先进技术IMRT计划需要修改并重新提交以满足方案标准。
  • 放疗前计划审查是宫颈癌临床试验的重要质量措施。

研究设计与样本

  • 各中心需通过标准化IMRT认证流程,并快速提交IMRT计划供专家审查靶区和危及器官轮廓及剂量。

主要发现

  • 中位随访20个月。
  • 重大偏差计划重新提交后,其中2例需再次修改,共3例计划需修改。

关键数值与推荐

  • 方案规定了IMRT轮廓指南和剂量细节,偏差分为方案内、次要偏差和重大偏差。
  • 重大偏差需修改并重新提交,治疗前再次审查。

临床怎么用

  • 局部晚期宫颈癌临床试验中应实施放疗前计划中心审查以确保方案依从性。
  • 先进技术IMRT计划需关注轮廓和剂量分布,常见重大偏差源于肠道和淋巴结轮廓。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Advances in radiation (RT) treatment planning enhance the need for uniform quality oversight on clinical trials. NRG GY-017 was a randomized trial of the anti-program ligand death 1 (PD-L1) antibody, atezolizumab, before and concurrent (arm A) or concurrent with chemoradiaton (arm B) for locally advanced cervical cancer. We describe the prospectively collected pretreatment RT quality and workflow. METHODS: Forty patients were consented and randomized. Thirty-seven patients submitted pretreatment RT plans for central review, and 36 patients ultimately received protocol therapy. Intensity modulated radiation therapy (IMRT) contouring guidelines and dose specifics were outlined in the protocol, with volume and dose deviations specified as per protocol, minor and major variation. Each site had to pass a standardized IMRT credentialing process. Sites were required to submit an IMRT plan for physician expert contour target and organ-at-risk review in a rapid pretreatment manner. An expert physician then scored the contours and plan as per protocol or as a deviation. For major deviations, the sites were required to revise and resubmit the plans, which were then re-reviewed prior to protocol start. RESULTS: The median follow-up time was 20 months. Thirty-seven participants had a central expert review of the pretreatment external beam radiation therapy plan. Thirteen plans (35%) were scored as a major deviation requiring revision: 11 secondary to contours (5 bowel and 6 nodal volumes) and 2 secondary to incorrect expansion on the volume or the dose distribution. The major deviation plans were resubmitted; however, 2 of them required revisions for a total of 3 plans. Because of the quality review, all patients had per-protocol scores prior to the treatment administration. CONCLUSIONS: Our data indicate that 35% of the baseline submitted advanced technology IMRT plans required revision and resubmission in order to meet protocol standards. RT plan quality workflow continues to evolve with advanced techniques and has implications in clinical trial review. Pretreatment plan review is an important quality measure for cervical cancer clinical trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mayadev J, Deng W, Kim H, et al. Radiation Quality and Workflow in NRG GY017: Anti-PD-L1 (Atezolizumab) as an Immune Primer or Concurrently With Radiation Therapy for Node-Positive Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42184868. doi:10.1016/j.ijrobp.2026.04.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。